A flowchart of the study showed that high COL19A1 expression conferred a good prognosis for esophageal squamous cell carcinoma (ESCC) patients, and it was also a novel biomarker for successful immunotherapy. This evidence concerns the gene COL19A1 and esophageal squamous cell carcinoma.